Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Fuji
UBS
Cerilliant
Colorcon
Farmers Insurance
Dow
US Army
Cantor Fitzgerald

Generated: November 19, 2018

DrugPatentWatch Database Preview

Ondansetron - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for ondansetron and what is the scope of ondansetron freedom to operate?

Ondansetron is the generic ingredient in nine branded drugs marketed by Midatech Pharma Us, Aurobindo Pharma, Barr, Chartwell Molecules, Glenmark Generics, Mylan, Nesher Pharms, Sandoz, Sun Pharm Inds, Sun Pharm Inds Ltd, Teva, Novartis Pharms Corp, Accord Hlthcare, Apotex Inc, Aurobindo Pharma Ltd, Baxter Hlthcare Corp, Emcure Pharms, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma Farmaceutica, Hospira, Lannett Co Inc, Luitpold, Mylan Labs Ltd, Pliva Hrvatska Doo, Qilu Pharm Co Ltd, Sagent Pharms, Sandoz Inc, Sun Pharm Inds (in), West-ward Pharms Int, Wockhardt, Emcure Pharms Ltd, Taro Pharms Ireland, Glaxosmithkline, Amneal Pharms, Apotex, Taro, Casi Pharms Inc, Dr Reddys Labs Ltd, Hikma Intl Pharms, Ipca Labs Ltd, and Natco Pharma Ltd, and is included in eighty-four NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are twenty-eight drug master file entries for ondansetron. Thirty-six suppliers are listed for this compound. There are three tentative approvals for this compound.

Pharmacology for ondansetron
Medical Subject Heading (MeSH) Categories for ondansetron
Synonyms for ondansetron
(RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one
1,2,3,4-Tetrahydro-9-methyl-3-(2-methyl-1H-imidazol-1-ylmethyl)carbazol-4-one
1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one
1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H- carbazol-4-one
1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one
1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1yl)methyl]-4H-carbazol-4-one
1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazole-1 -yl)methyl]-4H-carbazol-4-one
1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazole-1-yl)methyl]-4H-carbazol-4-one
1,2,3,9,-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one
103639-04-9
103639-04-9 (mono-hydrochloride dihydrate)
108303-49-7
116002-70-1
39O049
4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-
9-Methyl-3- (2-methyl-imidazol-1ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one
9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-1,2,3,9-tetrahydro-4H-carbazol-4-one
9-Methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-2,3-dihydro-1H-carbazol-4(9H)-one
9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
9-methyl-3-[(2-methylimidazolyl)methyl]-1,2,3,9-tetrahydro-4aH-carbazol-4-one
99614-01-4
99614-01-4 (mono-hydrochloride)
99614-02-5
AB0013753
AB00373674
AB00373674_18
AB00373674_19
AB00373674-15
AB00373674-17
AB2000413
AC1L1IIM
ACN-049703
ACT02589
AK-29654
AKOS000599484
AKOS016340526
AN-6592
Apo-ondansetron
BAS 00717177
BBL010304
BC220610
BCP9001025
BDBM85330
BPBio1_001118
BR-29654
BRD-A19736161-001-01-8
BRD-A19736161-003-03-0
BRN 3622981
BSPBio_001016
C07325
C18H19N3O
CAS_68647
CAS-99614-02-5
CBDivE_008994
CHEBI:7773
CHEMBL46
CPD001307702
CS-2393
CTK8G2184
D00456
D0K7WK
DB00904
DESMETHYLONDANSETRON
DR001119
DSSTox_CID_3393
DSSTox_GSID_23393
DSSTox_RID_77011
DTXSID8023393
FELGMEQIXOGIFQ-UHFFFAOYSA-N
FT-0631004
GR 38032
GR 38032X
GR-38032
GR-38032F
GR-38032F/GR-38032
GR38032F
GTPL2290
HMS2090H16
HMS3259H08
HMS3371E18
HSDB 8304
HY-B0002B
I06-0687
I06-1329
I544
KB-308401
KS-00000JSZ
KS-5227
L000456
LS-172305
LS-51878
MCULE-9438746800
MFCD00833882
MLS006011928
MolPort-001-944-253
NC00706
NCGC00179341-02
NCGC00179341-04
NCI60_022780
Novo-ondansetron
NSC_68647
Odansetron [common misspelling of ondansetron]
Ondansetron (JAN/USP/INN)
ondansetron (Zofran)
Ondansetron [USAN:INN:BAN]
Ondansetron [USP:INN:BAN]
Ondansetron Injection
Ondansetron, (+,-)-Isomer
Oprea1_435466
Oprea1_852372
PHL-ondansetron
PL042447
PMS-ondansetron
Prestwick0_001058
Prestwick1_001058
Prestwick2_001058
Prestwick3_001058
QC-660
Ratio-ondansetron
S-2116
s1996
SAM002589958
Sandoz ondansetron
SBB066158
SC-07554
SCHEMBL4542
SMR001307702
SN-307
SPBio_002938
ST077669
ST2412612
STK370548
STOCK4S-10990
TimTec1_001750
TL8006071
Tox21_113048
Tox21_113048_1
VA11441
Z1741971217
Zofran
Zofran (TN)
ZOFRAN IN PLASTIC CONTAINER
Zofran ODT
Zofran ODT (TN)
Zophren
Zudan
Zuplenz
Tentative approvals for ONDANSETRON
Applicant Application No. Strength Dosage Form
➤ Try a Free Trial➤ Try a Free TrialEQ 2MG BASE/MLINJECTABLE;INJECTION
➤ Try a Free Trial➤ Try a Free TrialEQ 2MG BASE/MLINJECTABLE;INJECTION
➤ Try a Free Trial➤ Try a Free Trial8MGTABLET, ORALLY DISINTEGRATING;ORAL

US Patents and Regulatory Information for ondansetron

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds (in) ONDANSETRON HYDROCHLORIDE ondansetron hydrochloride INJECTABLE;INJECTION 077172-001 Dec 26, 2006 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Dr Reddys Labs Ltd ONDANSETRON HYDROCHLORIDE ondansetron hydrochloride TABLET;ORAL 076183-002 Dec 26, 2006 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Aurobindo Pharma ONDANSETRON HYDROCHLORIDE ondansetron hydrochloride TABLET;ORAL 078539-003 Jul 31, 2007 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for ondansetron

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp ZOFRAN ODT ondansetron TABLET, ORALLY DISINTEGRATING;ORAL 020781-001 Jan 27, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp ZOFRAN ODT ondansetron TABLET, ORALLY DISINTEGRATING;ORAL 020781-001 Jan 27, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp ZOFRAN ODT ondansetron TABLET, ORALLY DISINTEGRATING;ORAL 020781-001 Jan 27, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Fuji
UBS
Cerilliant
Colorcon
Farmers Insurance
Dow
US Army
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.